What is Regenxbio's cash & equivalents?

Regenxbio (RGNX) reported cash & equivalents of $15.23M in Q1 2026.

How has Regenxbio's cash & equivalents changed year-over-year?

Regenxbio's cash & equivalents decreased by 88.3% year-over-year, from $130.1M to $15.23M.

What is the long-term trend for Regenxbio's cash & equivalents?

Over 5 years (2020 to 2025), Regenxbio's cash & equivalents has grown at a -36.7% compound annual growth rate (CAGR), from $338.43M to $34.47M.

What does cash & equivalents mean?

Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Regenxbio RGNX Cash & Equivalents

Cash & Equivalents at other companies

Regeneron PharmaceuticalsREGN

$2.97B-4.0%

Sarepta Therapeutics, Inc.SRPT

$464.45M+92.8%

BiogenBIIB

$3.38B+30.2%

BioMarin PharmaceuticalsBMRN

$3.07B+193%

EyePoint, Inc. EYPT

$77.71M-8.7%

Ultragenyx PharmaceuticalRARE

$175M+37.8%

Other financials

Income statement

See full

Revenue$6.4M-92.8%

Gross profit$14.9M+35.7%

Operating income-$83.4M-787%

Net income-$90.1M-1,580%

EPS (diluted)-$1.72-1,533%

Balance sheet

See full

Total debt$71.1M-11.0%

Total equity$21.1M-92.3%

Total assets$341.9M-30.4%

Cash flow

See full

Operating cash flow-$76.2M-327%

CapEx$1.2M+20.6%

Free cash flow-$77.4M-337%

Valuation

See full

Market cap$529.38M+24.6%

Enterprise value$585.22M+56.3%

P/S6×+3.3×

Profitability

See full

Gross margin59.7%+1.0pp

Operating margin-292.3%-613pp

Net margin-330.2%-588pp

FCF margin-269.2%-364pp

Returns & leverage

See full

Return on equity-196.4%-288pp

Debt / equity3.4×+3.1×

Current ratio2.6×-0.3×

Where this comes from

Reported directly by Regenxbio in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: Regenxbio’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Regenxbio's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Regenxbio's cash & equivalents?: Regenxbio (RGNX) reported cash & equivalents of $15.23M in Q1 2026.
How has Regenxbio's cash & equivalents changed year-over-year?: Regenxbio's cash & equivalents decreased by 88.3% year-over-year, from $130.1M to $15.23M.
What is the long-term trend for Regenxbio's cash & equivalents?: Over 5 years (2020 to 2025), Regenxbio's cash & equivalents has grown at a -36.7% compound annual growth rate (CAGR), from $338.43M to $34.47M.
What does cash & equivalents mean?: Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.